Cormorant Asset Management BIOA Position
Active5-Fund ConvergenceCormorant Asset Management trimmed their position in BioAge Labs, Inc. (BIOA) in Q4 2025, holding $27.0M worth of shares across 2,040,605 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
BIOA is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Full company profile →Short Interest
3.5%
2.4 days to cover
Cormorant Asset Management BIOA Position History
Frequently Asked Questions
Does Cormorant Asset Management own BIOA?
Yes. As of Q4 2025, Cormorant Asset Management holds 2,040,605 shares of BioAge Labs, Inc. (BIOA) valued at $27.0M. This data comes from their SEC 13F filing.
How many hedge funds own BIOA?
5 specialist biotech hedge funds currently hold BIOA, including RA Capital Management, OrbiMed Advisors, RTW Investments and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy BIOA?
Cormorant Asset Management's position in BIOA was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's BIOA position increasing or decreasing?
Cormorant Asset Management trimmed their BIOA position in the most recent quarter, reducing by 100,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BIOACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →